Castle Biosciences (CSTL) Q2 2026: TissueCypher Volumes Surge 63% as Pipeline Expansion Accelerates

2026-07-30 | By EarningsIQ Research

TissueCypher, Barrett’s esophagus risk test, drove standout growth for Castle Biosciences in Q2 2026, with volumes up 63% year over year and management raising full-year revenue guidance. Investment in commercial resources, evidence generation, and pipeline expansion is reshaping the business mix, but margin compression and rising expenses signal a deliberate, growth-centric phase that investors must monitor for scalability and returns.

Summary

• TissueCypher Penetration Expands: Volume growth leads, but runway remains as penetration is still in the teens.
• Margin Compression Signals Investment Cycle: Growth investments outpace revenue leverage, impacting profitability metrics.
• Pipeline and Commercial Model in Transition: R&D and field force allocation shifting to support new launches and future revenue streams.

Business Overview

Castle Biosciences develops and commercializes diagnostic and prognostic tests for dermatology and gastroenterology, focusing on molecular diagnostics that inform patient management and therapy selection. Revenue is primarily generated from proprietary tests such as DecisionDx Melanoma (skin cancer risk stratification), TissueCypher (Barrett’s esophagus progression risk), and Advanced ADTX (atopic dermatitis therapy guidance), with additional pipeline assets in development. The business model leverages clinical evidence to drive payer reimbursement and clinician adoption, with revenue mix evolving as new tests scale.

Performance Analysis

Castle Biosciences delivered $103.5 million in Q2 revenue, up 20% year over year, with core growth driven by TissueCypher’s 63% volume surge and incremental improvement in average selling price (ASP). Excluding legacy or de-emphasized products (DecisionDx SCC and IDGenX), underlying revenue growth reached 40%. Test report volume for core drivers increased 32% year over year, highlighting broad-based adoption.

However, gross margin compressed to 74.9% from 77.3% in the prior year, and operating expenses rose to $106.6 million, up from $90.4 million, reflecting deliberate investments in commercial, R&D, and administrative headcount. Adjusted EBITDA improved to $12.4 million, but the company swung to a net loss of $2.1 million as growth investment outpaced leverage. Cash and marketable securities totaled $266.8 million, supporting ongoing pipeline and commercial expansion.

• TissueCypher Volume Growth: 14,988 test reports, up 63% YoY, with management guiding to 50–52% full-year growth and penetration still in the mid-teens.
• DecisionDx Melanoma Steady: 10,280 reports, 3% YoY growth, with sequential growth below seasonal norms due to salesforce realignment.
• Advanced ADTX Early Traction: Over 1,000 orders, with strong clinical evidence and reimbursement progress, but still in early-stage, controlled rollout.

Revenue guidance was raised to $365–375 million for 2026, reflecting confidence in core test momentum, though margin and cost trends warrant scrutiny as the business pivots to multi-product scale.

Executive Commentary

Strategic Positioning

1. TissueCypher as the Primary Growth Engine

TissueCypher, Barrett’s esophagus progression test, is now Castle’s leading growth driver, with penetration still in the early innings—management estimates mid-teens percent of the addressable market. The commercial model is calibrated for further expansion, but management acknowledges that converting later adopters will require sustained sales and education investment.

2. Commercial Model Realignment

Salesforce focus has shifted, with dermatology reps now carrying three products per call. This has tempered sequential growth in DecisionDx Melanoma but is designed to maximize cross-sell and long-term account value. Expansion in sales territories for both dermatology and gastroenterology is largely complete, with recent hires yet to reach full productivity.

3. Pipeline and R&D Prioritization

R&D spend is trending upward, reflecting a deliberate pivot to pipeline expansion, especially in existing therapeutic areas where Castle’s commercial footprint is established. The Advanced ADTX test and GI pipeline (including PROVISE assets and new cell collection devices) are prioritized for mid- and long-term value creation.

4. Evidence Generation and Reimbursement

Clinical evidence remains central, as recent publications and multicenter studies reinforce test utility and support payer negotiations. The crosswalk panel’s unanimous vote and strong rate recommendation for Advanced ADTX are expected to accelerate commercial payer discussions, though full-scale launch is staged for when reimbursement is more predictable.

5. Margin and Capital Allocation Discipline

Gross margin compression and rising opex reflect growth investments, but management signals ongoing discipline and a focus on positive adjusted EBITDA for the remainder of 2026 and into 2027. The strong cash position supports continued investment without near-term capital risk.

Key Considerations

Castle’s Q2 reflects a business in transition, scaling beyond its legacy melanoma franchise with a multi-pronged commercial and pipeline strategy. Investors should weigh the durability of high growth in TissueCypher, the path to margin recovery, and the ability to drive repeat utilization in new launches.

Key Considerations:

• TissueCypher Runway: Penetration remains in the mid-teens, with significant addressable market left but conversion of later adopters could slow growth pace.
• Margin Pressure: Investment in field force and R&D is compressing margins, with adjusted gross margin now guided to low-to-mid 70s for the year.
• Salesforce Productivity Lag: Recent territory expansions have not yet fully contributed, suggesting potential for further operating leverage if volumes scale.
• Advanced ADTX Commercialization: Early clinical traction and payer momentum are positive, but broad rollout is gated by reimbursement certainty and internal collection model validation.
• Regulatory and Payer Uncertainty: Medicare coverage for DecisionDx SCC and pipeline GI tests remains unresolved, with timelines for LCD reconsideration and FDA breakthrough device approval still fluid.

Risks

Margin compression and rising costs highlight the risk that growth investments may not translate into scalable, profitable revenue if adoption slows or payer dynamics shift. Reimbursement exposure remains material, especially for pipeline assets and products awaiting LCD reconsideration or commercial payer traction. Competitive pressure in dermatology and GI diagnostics, alongside the challenge of converting later-stage adopters, could temper growth rates and test ASPs.

Forward Outlook

For Q3 2026, Castle expects:

• Continued strong volume growth in TissueCypher, trending toward 50–52% full-year increase.
• DecisionDx Melanoma volumes to deliver mid to high single-digit annual growth, with sequential acceleration possible as salesforce productivity normalizes.

For full-year 2026, management raised guidance:

• Total revenue of $365–375 million, up from $345–355 million prior.
• Adjusted gross margin in the low to mid 70s range.

Management cited robust pipeline progress, clinical evidence generation, and strong balance sheet as supports for sustained investment and future growth. Key watchpoints include payer decisions, field force productivity, and Advanced ADTX commercial launch timing.

• Continued clinical evidence to support reimbursement and adoption.
• Monitoring of margin trends as investments scale.

Takeaways

Castle’s Q2 marks a pivotal quarter, with TissueCypher’s breakout growth and pipeline momentum offset by margin pressure and cost escalation. The business is deliberately investing for long-term leadership in molecular diagnostics, but execution on commercial expansion, payer wins, and operational leverage will determine the pace and durability of value creation.

• TissueCypher Volume Outperformance: Core driver of revenue growth, but long-term trajectory depends on converting harder-to-reach physicians and sustaining ASPs.
• Margin and Cost Structure in Focus: Investments are necessary for pipeline and commercial expansion, but investors should track the inflection to operating leverage and margin recovery.
• Pipeline and Reimbursement Milestones: Progress on Advanced ADTX, GI pipeline, and LCD reconsideration are critical catalysts for future quarters and overall business mix transformation.

Conclusion

Castle Biosciences’ Q2 2026 results highlight a business in strategic transition, with exceptional growth in TissueCypher and an expanding pipeline offset by margin compression and rising costs. The company’s ability to translate growth investments into durable, profitable revenue will be the key test as it seeks to lead in molecular diagnostics across multiple specialties.

Industry Read-Through

Castle’s Q2 underscores the importance of evidence-driven adoption and payer alignment in molecular diagnostics. The company’s success scaling TissueCypher points to significant unmet demand for actionable risk stratification tools in GI and dermatology, but also highlights the operational and margin headwinds faced by companies investing ahead of revenue. Broader industry implications include the need for robust clinical utility data, disciplined commercial expansion, and proactive payer engagement. Players in adjacent diagnostics and specialty testing will need to balance growth ambitions with margin discipline as the market matures and competition intensifies.

CSTL Healthcare Diagnostics Molecular Testing Pipeline Reimbursement Margin Growth